Clinical Pharmacology in Neonates: Small Size, Huge Variability
Authors:
Open Access
- 30 May 2014
- journal article
- review article
- Published by S. Karger AG in Neonatology
- Vol. 105 (4) , 344-349
Abstract
Drug therapy is a powerful tool for improving neonatal outcome. Despite this, neonatologists still routinely prescribe off-label compounds developed for adults and extrapolate doses from those used for children or adults. Knowledge integration through pharmacokinetic modeling is a method that could improve the current situation. Such predictive models may convert neonatal pharmacotherapy from explorative to confirmatory. This can be illustrated by research projects related to the prediction of neonatal renal clearance and neonatal glucuronidation. This type of model will also improve the current knowledge of neonatal (patho)physiology. In the meanwhile, the fields of clinical pharmacology (e.g. pharmacokinetic/pharmacodynamic modeling and pharmacogenetics) and neonatology (e.g. whole-body cooling and the lower limit of viability) have both matured, resulting in new research topics. However, in order for the modeling and the newly emerging topics to become effective tools, they need to be tailored to the specific characteristics of neonates. Consequently, the field of neonatal pharmacotherapy needs dedicated neonatologists who continue to raise the awareness that off-label practices, eminence-based dosing regimens and the absence of neonatal drug formulations all reflect suboptimal care.Keywords
This publication has 32 references indexed in Scilit:
- A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in NeonatesPharmaceutical Research, 2013
- European Consensus Guidelines on the Management of Neonatal Respiratory Distress Syndrome in Preterm Infants - 2013 UpdateNeonatology, 2013
- An Algorithm to Detect Adverse Drug Reactions in the Neonatal Intensive Care UnitThe Journal of Clinical Pharmacology, 2013
- From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part I–Extrapolation of a Covariate Model From Morphine to ZidovudineCPT: Pharmacometrics & Systems Pharmacology, 2012
- External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settingsBritish Journal of Clinical Pharmacology, 2012
- The Pharmacogenetics of NAT2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving IsoniazidThe Journal of Clinical Pharmacology, 2012
- First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug developmentJournal of Pharmacokinetics and Pharmacodynamics, 2012
- Individualized dosing regimens in children based on population PKPD modelling: Are we ready for it?International Journal of Pharmaceutics, 2011
- The role of population PK–PD modelling in paediatric clinical researchEuropean Journal of Clinical Pharmacology, 2010
- Covariates of tramadol disposition in the first months of lifeBritish Journal of Anaesthesia, 2008